COMMUNITY-BASED MANAGEMENT OF SEVERE ACUTE …

S evere acute malnutrition remains a major killer of children under five years of age. Until recently, treatment has been restricted to facility-based approaches, greatly

  Based, Management, Community, Severe, Acute, Reeves, Community based management of severe acute, S evere acute

International Guidelines for Management of Severe Sepsis ...

Other Supportive Therapy of Severe Sepsis blood product adminiStration • Once tissue hypoperfusion has resolved and in the absence of extenuating circumstances, such as myocardial ischemia, severe hypoxemia, acute hemorrhage, or ischemic heart

  Sepsis, Acute

Stony Brook Medicine Severe Sepsis/Septic Shock ...

1 Stony Brook Medicine Severe Sepsis/Septic Shock Recognition and Treatment Protocols Subject: Severe Sepsis/Septic Shock Published Date: August 9, 2013

  Shocks, Sepsis, Severe, Recognition, Septic, Severe sepsis septic shock, Severe sepsis septic shock recognition

Hormonal Contraception - Supplementary Tables …

Contraceptive, Hormonal Products – Prescription S. Downey, L. Regier - www.RxFiles.ca Sept 04 BRAND NAME Hormonal Activity Oral Contraceptives (OC) COMPONENTS E=estrogen P=Progestin A=Androgen E P A $ Cost

  Supplementary, Table, Hormonal, Contraception, Hormonal contraception supplementary tables

DRUG NAME: Dasatinib - BC Cancer

Dasatinib DRUG NAME: Dasatinib SYNONYM(S): BMS 354825 1. COMMON TRADE NAME(S): SPRYCEL® CLASSIFICATION: tyrosine kinase inhibitor. Special pediatric considerations are noted when applicable, otherwise adult provisions apply.

  Dasatinib

Behind every healthy 19Aug16 - Yale School of Medicine

Behind Every Healthy Baby is a Healthy Placenta© Harvey J. Kliman, M.D., Ph.D. Yale University School of Medicine harvey.kliman@yale.edu A healthy placenta is the single most important factor in producing a healthy baby.

  School, Medicine, Every, Behind, Yale, Healthy, Behind every healthy, Yale school of medicine

RXFILES TRIAL SUMMARY WWW JULY 2016; UPDATED MAY …

RXFILES TRIAL SUMMARY WWW JULY 2016; UPDATED MAY 2017 – .RXFILES.CA Page 1 of 3 LEADER: Liraglutide VICTOZA CV Outcomes Trial Summary 1 Liraglutide: Cardiovascular (CV) Outcomes and Mortality in Patients with Type 2 Diabetes (T2DM) In patients with T2DM and at high risk of CV events, does liraglutide reduce CV risk compared to placebo when added to standard care?